Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2004

View Archived Issues

New subunit-selective GABA-A receptor ligands developed at Merck

New antiangiogenic agents prepared and tested at ExonHit

Two series of chemokine CCR8 antagonists claimed by GSK researchers

Biofrontera presents a novel antibiotic with anti-H. pylori activity

Novel glucocorticoid receptor modulators designed at Boehringer Ingelheim

Schering AG presents three series of estratriene-based antimitotic agents

GSK patent covers new anti-HCV NS5B inhibitors

Provid scientists present new MHC binding modulators for multiple sclerosis and other disorders

Rivastigmine reported to improve cognition in schizophrenic patients

Clinical evidence of the effects of the SERM HMR-3339 in postmenopausal women

PBT-1 to enter phase II/III study in 2005

Chiron submits Pulminiq NDA

Pramipexole for Parkinson's disease returns to Boehringer Ingelheim

AERES Biomedical completes humanization of Peregrine's 3G4 antibody

Traditional approval for Fuzeon

European approval for Kogenate Bayer with Bio-Set

Hedley Technologies to acquire Medicor

Arpida acquires Combio

FDA approval for Campath single-dose vial

Second phase I study for SNS-595

Cambrex to market and distribute Orcel

Tissue Repair Cell study expanded

R&D highlights from the 4th Annual Biotech In Europe Investor Forum: Genetronics Biomedical

Pfizer sponsors new study of Celebrex

Phase III findings on Ampligen for chronic fatigue syndrome

Argenes and Santen sign Japanese agreement for anti-APO-1 antibody

Vardenafil subject of various presentations at ISSIR

ACE inhibitors show promise in Alzheimer's disease

CP-113818 reduces amyloid plaques in Alzheimer's model

Prous Science webcasts key lecture sessions from the 27th SIU Congress

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...